GHK-Cu: A Copper Signal for Skin's Repair Matrix

The short version

GHK-Cu is a tiny peptide — three amino acids: glycine, histidine, lysine — bound to a single copper ion. It is also called copper tripeptide-1. The same GHK sequence occurs naturally inside type I collagen, the main structural protein of skin and tendon, which is a clue to what it does: it signals skin cells called dermal fibroblasts to produce more collagen, elastin, and the supporting molecules that make up healthy connective tissue ^[4].

Of the two compounds on this desk, GHK-Cu has the most human evidence. But that evidence is mostly topical — creams and serums applied to the skin surface — and it comes with a built-in catch: GHK-Cu crosses intact skin poorly ^[1]. The 2025 review that best summarizes this challenge reports procollagen synthesis up in 70% of GHK-Cu-treated subjects versus 50% for vitamin C and 40% for retinoic acid, and evaluates techniques like palmitoylation and microneedling to push more peptide through ^[1]. Topical copper-peptide cosmetics are legal and widely sold. Injectable or systemic use is unapproved and research-only. This page summarizes the published findings and recommends nothing.

What it is

GHK-Cu is a linear tripeptide — glycyl-L-histidyl-L-lysine — chelated one-to-one to a copper(II) ion. The copper is held in place by the histidine imidazole nitrogen, the glycine alpha-amino nitrogen, and a deprotonated backbone nitrogen, while the lysine side chain remains free. The complex carries a small positive charge.

The bare GHK tripeptide sequence occurs naturally within the alpha-2(I) chain of type I collagen and in the matrix protein SPARC/osteonectin — which means the body already produces and recognizes this motif. Copper coordination is required for most of its reported bioactivities; the free tripeptide GHK and the copper chelate GHK-Cu are frequently conflated in secondary sources, but the form used in any given study genuinely matters ^[4].

How it works

GHK-Cu operates as both a copper chaperone — a carrier that delivers copper where it is needed — and a broad signaling molecule. At picomolar-to-nanomolar concentrations it directly stimulates dermal fibroblasts to synthesize collagen, elastin, glycosaminoglycans and the proteoglycan decorin, while simultaneously rebalancing matrix metalloproteinases (enzymes that break down matrix) against their natural inhibitors (TIMPs) ^[4][6]. The copper ion also enables lysyl oxidase-mediated cross-linking that knits collagen and elastin fibers together, plus a superoxide-dismutase-like antioxidant action.

At a cellular level, the collagen-stimulating effect is concentration-dependent: in human fibroblast cultures, stimulation began between 10 picomolar and 10 nanomolar, maximized at 1 nanomolar, and was independent of any change in cell number — indicating a direct metabolic signal, not simple proliferation ^[7].

At the gene level, a Connectivity Map analysis reported that GHK shifts expression of roughly 31.2% of human genes at a 50%-or-greater change threshold, with 59% of affected genes going up and 41% down ^[2]. The upregulated programs include the ubiquitin-proteasome quality-control system, DNA-repair pathways, and antioxidant gene sets. One honest correction: the widely quoted "~4,000 genes" figure is an extrapolation — the verified 50%-threshold table reports on the order of 2,100 genes ^[2].

What the research shows

Skin regeneration and collagen. The 2015 canonical review documents GHK-Cu stimulating synthesis of collagen, dermatan sulfate, chondroitin sulfate and decorin; notes that plasma GHK falls from about 200 ng/mL at age 20 to about 80 ng/mL by age 60; and reports that topical GHK-Cu increased collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid, with documented clinical improvements in skin laxity, clarity, fine lines and wrinkle depth ^[4].

Gene expression. The 2018 analysis quantified the transcriptomic shift toward repair, protein quality control, DNA fidelity and antioxidant programs across roughly 31.2% of human genes at the 50%-change threshold ^[2].

Hair growth (controlled human trial). In a 6-month RCT of 45 men with androgenetic alopecia, a formulation combining 5-aminolevulinic acid with glycyl-histidyl-lysine peptide increased hair count by 52.6 (100 mg/mL) and 71.5 (50 mg/mL) versus only 9.6 for placebo (p < 0.05), with no adverse events ^[3]. This is the strongest controlled human efficacy signal for a GHK-containing topical — though it is a combination product, not pure GHK-Cu alone.

Delivery and formulation. The 2025 review confirms that GHK's poor stratum-corneum permeability (clogP -2.24) is the central challenge, and evaluates palmitoylation (Pal-GHK, clogP 1.14) and microneedle pretreatment (~134 nmol GHK permeated versus none through intact skin) as enhancement strategies ^[1]. A separate human skin-penetration study using dermatomed skin measured a permeability coefficient of 2.43 ± 0.51 × 10⁻⁴ cm/h, with 136.2 µg/cm² of copper permeating over 48 hours and a dermal depot forming ^[5].

Tissue remodeling review. A 2008 review compiled GHK-Cu's full tissue-remodeling profile across human and animal studies: increased synthesis of collagen, elastin, metalloproteinases and anti-proteases, VEGF, FGF-2, NGF, and erythropoietin, alongside suppression of free radicals, TGF-beta-1, TNF-alpha, and protein glycation ^[6].

Reported effects, cautions & safety

Topical copper-peptide cosmetics carry a long real-world safety record. For systemic or injectable use, the picture is different. Several cautions stand out in the literature:

• No approved therapeutic indication. There is no FDA- or EMA-approved GHK-Cu drug product by any route. Topical Copper Tripeptide-1 is a legal cosmetic ingredient; injectable or systemic use is unapproved and research-only ^[1].
• Limited human clinical evidence. Human data are confined to small topical dermatology trials (n approximately 13–71) and one 45-patient combination hair-loss RCT, not a pure GHK-Cu study ^[3]. There are no validated human pharmacokinetic data for injectable use, so community protocols have no peer-reviewed basis.
• Delivery challenge. The poor permeability of native GHK-Cu (clogP -2.24) means only a fraction reaches the dermis without a delivery system; novel approaches are early-stage ^[1].
• Localized hyperpigmentation. Skin darkening has been reported in some topical copper-peptide applications — for example, around 40% in one acne-scar microneedling study.
• Formulation incompatibility. Vitamin C (ascorbic acid) and low-pH acids can reduce Cu(II) or create competition, destroying both actives — a real user-error risk.
• Theoretical copper accumulation. Prolonged systemic use raises a theoretical copper-balance concern, though no human copper-toxicity case attributed to GHK-Cu appears in the peer-reviewed record.
• Single-investigator concentration. A large share of foundational mechanistic and review literature traces to one investigator and colleagues, limiting independent replication of the broader gene-expression and anti-aging claims ^[2].

Where it fits in skin research

GHK-Cu is the matrix-and-skin specialist on this desk, and the one with the most human evidence — but that evidence is mostly topical, capped by the peptide's own delivery problem ^[1]. Its decades of cosmetic use give it a safety footprint that most research peptides lack; what it lacks is validated systemic human data. In the context of the GLOW blend, GHK-Cu contributes the matrix-building leg: collagen synthesis, elastin cross-linking, and the broad gene-expression remodeling that researchers associate with tissue maintenance and repair ^[6]. See the comparison page for how it lines up against GLOW.